A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial

Takuya Sadahira; Yuki Maruyama; Yoshiki Hiyama; Hiroyuki Kitano; Hiroki Yamada; Takayuki Goto; Tsubasa Kondo; Katsumi Shigemura; Yosuke Mitsui; Takehiro Iwata; Kohei Edamura; Motoo Araki; Masami Watanabe; Tadasu Takenaka; Jun Teishima; Yasuyoshi Miyata; Kiyohito Ishikawa; Ei Ichiro Takaoka; Jun Miyazaki; Satoshi Takahashi; Naoya Masumori; Hiroshi Kiyota; Masato Fujisawa; Shingo Yamamoto; Takafumi Sakuma; Norihiro Kusumi; Takaharu Ichikawa; Toyohiko Watanabe; Yoshitsugu Nasu; Masaya Tsugawa; Yasutomo Nasu; Koichiro Wada

A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial

Takuya Sadahira
, Yuki Maruyama
, Yoshiki Hiyama
, Hiroyuki Kitano
, Hiroki Yamada
, Takayuki Goto
, Tsubasa Kondo
, Katsumi Shigemura
, Yosuke Mitsui
, Takehiro Iwata
, Kohei Edamura
, Motoo Araki
, Masami Watanabe
, Tadasu Takenaka
, Jun Teishima
, Yasuyoshi Miyata
, Kiyohito Ishikawa
, Ei Ichiro Takaoka
, Jun Miyazaki
, Satoshi Takahashi

Naoya Masumori, Hiroshi Kiyota, Masato Fujisawa, Shingo Yamamoto, Takafumi Sakuma, Norihiro Kusumi, Takaharu Ichikawa, Toyohiko Watanabe, Yoshitsugu Nasu, Masaya Tsugawa, Yasutomo Nasu, Koichiro Wada

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

2 被引用数 (Scopus)

抄録

The aim of this report is to introduce an on-going, multicenter, randomized controlled trial to evaluate whether tailored antimicrobial prophylaxis guided by rectal culture screening prevents acute bacterial prostatitis following transrectal prostate biopsy (TRPB). Patients will be randomized into an intervention or non-intervention group; tazobactam-piperacillin or levofloxacin will be prophylactically administered according to the results of rectal culture prior to TRPB in the intervention group whereas levofloxacin will be routinely given in the non-intervention group. The primary endpoint is the occurrence rate of acute bacterial prostatitis after TRPB. Recruitment begins in April, 2021 and the target total sample size is 5,100 participants.

本文言語	英語
ページ（範囲）	663-667
ページ数	5
ジャーナル	Acta Medica Okayama
巻	75
号	5
出版ステータス	出版済み - 2021
外部発表	はい

All Science Journal Classification (ASJC) codes

生化学、遺伝学、分子生物学一般

他のファイルとリンク

フィンガープリント

「A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Sadahira, T., Maruyama, Y., Hiyama, Y., Kitano, H., Yamada, H., Goto, T., Kondo, T., Shigemura, K., Mitsui, Y., Iwata, T., Edamura, K., Araki, M., Watanabe, M., Takenaka, T., Teishima, J., Miyata, Y., Ishikawa, K., Takaoka, E. I., Miyazaki, J., ... Wada, K. (2021). A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial. Acta Medica Okayama, 75(5), 663-667.

@article{aa461c29ed4b4004827897c529e9b67a,

title = "A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial",

abstract = "The aim of this report is to introduce an on-going, multicenter, randomized controlled trial to evaluate whether tailored antimicrobial prophylaxis guided by rectal culture screening prevents acute bacterial prostatitis following transrectal prostate biopsy (TRPB). Patients will be randomized into an intervention or non-intervention group; tazobactam-piperacillin or levofloxacin will be prophylactically administered according to the results of rectal culture prior to TRPB in the intervention group whereas levofloxacin will be routinely given in the non-intervention group. The primary endpoint is the occurrence rate of acute bacterial prostatitis after TRPB. Recruitment begins in April, 2021 and the target total sample size is 5,100 participants.",

keywords = "antibiotic prophylaxis, extended-spectrum beta-lactamase, fluoroquinolone-resistant, prostate biopsy, selective culture media",

author = "Takuya Sadahira and Yuki Maruyama and Yoshiki Hiyama and Hiroyuki Kitano and Hiroki Yamada and Takayuki Goto and Tsubasa Kondo and Katsumi Shigemura and Yosuke Mitsui and Takehiro Iwata and Kohei Edamura and Motoo Araki and Masami Watanabe and Tadasu Takenaka and Jun Teishima and Yasuyoshi Miyata and Kiyohito Ishikawa and Takaoka, \{Ei Ichiro\} and Jun Miyazaki and Satoshi Takahashi and Naoya Masumori and Hiroshi Kiyota and Masato Fujisawa and Shingo Yamamoto and Takafumi Sakuma and Norihiro Kusumi and Takaharu Ichikawa and Toyohiko Watanabe and Yoshitsugu Nasu and Masaya Tsugawa and Yasutomo Nasu and Koichiro Wada",

note = "Publisher Copyright: {\textcopyright} 2021. by Okayama University Medical School.",

year = "2021",

language = "English",

volume = "75",

pages = "663--667",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "5",

}

Sadahira, T, Maruyama, Y, Hiyama, Y, Kitano, H, Yamada, H, Goto, T, Kondo, T, Shigemura, K, Mitsui, Y, Iwata, T, Edamura, K, Araki, M, Watanabe, M, Takenaka, T, Teishima, J, Miyata, Y, Ishikawa, K, Takaoka, EI, Miyazaki, J, Takahashi, S, Masumori, N, Kiyota, H, Fujisawa, M, Yamamoto, S, Sakuma, T, Kusumi, N, Ichikawa, T, Watanabe, T, Nasu, Y, Tsugawa, M, Nasu, Y & Wada, K 2021, 'A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial', Acta Medica Okayama, vol. 75, no. 5, pp. 663-667.

A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial. / Sadahira, Takuya; Maruyama, Yuki; Hiyama, Yoshiki その他.
In: Acta Medica Okayama, Vol. 75, No. 5, 2021, p. 663-667.

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

TY - JOUR

T1 - A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy

T2 - A Multicenter, Randomized Controlled Trial

AU - Sadahira, Takuya

AU - Maruyama, Yuki

AU - Hiyama, Yoshiki

AU - Kitano, Hiroyuki

AU - Yamada, Hiroki

AU - Goto, Takayuki

AU - Kondo, Tsubasa

AU - Shigemura, Katsumi

AU - Mitsui, Yosuke

AU - Iwata, Takehiro

AU - Edamura, Kohei

AU - Araki, Motoo

AU - Watanabe, Masami

AU - Takenaka, Tadasu

AU - Teishima, Jun

AU - Miyata, Yasuyoshi

AU - Ishikawa, Kiyohito

AU - Takaoka, Ei Ichiro

AU - Miyazaki, Jun

AU - Takahashi, Satoshi

AU - Masumori, Naoya

AU - Kiyota, Hiroshi

AU - Fujisawa, Masato

AU - Yamamoto, Shingo

AU - Sakuma, Takafumi

AU - Kusumi, Norihiro

AU - Ichikawa, Takaharu

AU - Watanabe, Toyohiko

AU - Nasu, Yoshitsugu

AU - Tsugawa, Masaya

AU - Nasu, Yasutomo

AU - Wada, Koichiro

PY - 2021

Y1 - 2021

N2 - The aim of this report is to introduce an on-going, multicenter, randomized controlled trial to evaluate whether tailored antimicrobial prophylaxis guided by rectal culture screening prevents acute bacterial prostatitis following transrectal prostate biopsy (TRPB). Patients will be randomized into an intervention or non-intervention group; tazobactam-piperacillin or levofloxacin will be prophylactically administered according to the results of rectal culture prior to TRPB in the intervention group whereas levofloxacin will be routinely given in the non-intervention group. The primary endpoint is the occurrence rate of acute bacterial prostatitis after TRPB. Recruitment begins in April, 2021 and the target total sample size is 5,100 participants.

AB - The aim of this report is to introduce an on-going, multicenter, randomized controlled trial to evaluate whether tailored antimicrobial prophylaxis guided by rectal culture screening prevents acute bacterial prostatitis following transrectal prostate biopsy (TRPB). Patients will be randomized into an intervention or non-intervention group; tazobactam-piperacillin or levofloxacin will be prophylactically administered according to the results of rectal culture prior to TRPB in the intervention group whereas levofloxacin will be routinely given in the non-intervention group. The primary endpoint is the occurrence rate of acute bacterial prostatitis after TRPB. Recruitment begins in April, 2021 and the target total sample size is 5,100 participants.

KW - antibiotic prophylaxis

KW - extended-spectrum beta-lactamase

KW - fluoroquinolone-resistant

KW - prostate biopsy

KW - selective culture media

UR - https://www.scopus.com/pages/publications/85118634826

UR - https://www.scopus.com/pages/publications/85118634826#tab=citedBy

M3 - Article

C2 - 34703052

AN - SCOPUS:85118634826

SN - 0386-300X

VL - 75

SP - 663

EP - 667

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 5

ER -